Apomorphine subcutaneous infusion in patients with Parkinson's disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial

医学 阿扑吗啡 安慰剂 耐受性 左旋多巴 帕金森病 麻醉 运动障碍 临床终点 不利影响 临床试验 内科学 疾病 多巴胺能 多巴胺 替代医学 病理
作者
Regina Katzenschlager,Werner Poewe,Olivier Rascol,Claudia Trenkwalder,Günther Deuschl,К. Ray Chaudhuri,Tove Henriksen,Teus van Laar,Kevin Spivey,Senthil Vel,Harry Staines,Andrew J. Lees
出处
期刊:Lancet Neurology [Elsevier BV]
卷期号:17 (9): 749-759 被引量:217
标识
DOI:10.1016/s1474-4422(18)30239-4
摘要

Summary

Background

Subcutaneous apomorphine infusion is a clinically established therapy for patients with Parkinson's disease with motor fluctuations not optimally controlled by oral medication. Open-label studies have shown that apomorphine infusion is effective in reducing off time (periods when antiparkinsonian drugs have no effect), dyskinesias, and levodopa dose, but confirmatory evidence from double-blind, controlled studies is lacking. We aimed to investigate the efficacy and safety of apomorphine infusion compared with placebo in patients with Parkinson's disease with persistent motor fluctuations despite optimised oral or transdermal treatment.

Methods

In this randomised, placebo-controlled, double-blind, multicentre trial, we enrolled patients at 23 European hospitals who had been diagnosed with Parkinson's disease more than 3 years previously and had motor fluctuations not adequately controlled by medical treatment. Patients were randomly assigned (1:1) with a computer-generated randomisation code, stratified by site, to receive 3–8 mg/h apomorphine or placebo saline infusion during waking hours (16 h a day [range 14–18 was acceptable]) for 12 weeks. The flow rate of the study drug and other oral medications could be adjusted during the first 4 weeks on the basis of individual efficacy and tolerability, after which patients entered an 8-week maintenance period. The primary endpoint was the absolute change in daily off time based on patient's diaries, and was assessed in the full analysis set, which was defined as all patients who received at least one dose of allocated study drug and had efficacy data available at any timepoint post-baseline. Safety was assessed in all patients who received at least one dose of apomorphine or placebo. All study participants and investigators were masked to treatment assignment. Both the 12-week double-blind phase and the 52-week open-label phase of this study are now complete; this paper reports results for the double-blind phase only. This study is registered with ClinicalTrials.gov (NCT02006121).

Findings

Between March 3, 2014, and March 1, 2016, 128 patients were screened for eligibility and 107 were randomly assigned, of whom 106 were included in the full analysis set (n=53 in both groups). Apomorphine infusion (mean final dose 4·68 mg/h [SD 1·50]) significantly reduced off time compared with placebo (−2·47 h per day [SD 3·70] in the apomorphine group vs −0·58 h per day [2·80] in the placebo group; difference −1·89 h per day, 95% CI −3·16 to −0·62; p=0·0025). Apomorphine was well tolerated without any unexpected safety signals. Six patients in the apomorphine group withdrew from the study because of treatment-related adverse events.

Interpretation

Apomorphine infusion results in a clinically meaningful reduction in off time in patients with Parkinson's disease with persistent motor fluctuations despite optimised oral or transdermal therapy.

Funding

Britannia Pharmaceuticals.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
jinxichen完成签到,获得积分10
刚刚
xixixi发布了新的文献求助10
1秒前
1秒前
Aliothae发布了新的文献求助10
2秒前
任性冰凡完成签到,获得积分10
2秒前
完美世界应助好困采纳,获得30
2秒前
2秒前
3秒前
酷波er应助lqllll采纳,获得10
3秒前
4秒前
黎黎发布了新的文献求助10
4秒前
jjjjj完成签到,获得积分10
4秒前
4秒前
博士后发布了新的文献求助10
5秒前
5秒前
kyt发布了新的文献求助10
5秒前
旎旎发布了新的文献求助10
5秒前
6秒前
7秒前
NexusExplorer应助Aliothae采纳,获得10
7秒前
刘奇完成签到 ,获得积分10
7秒前
小魏小魏完成签到,获得积分10
7秒前
加减法号发布了新的文献求助10
8秒前
大学生发布了新的文献求助10
9秒前
keyan完成签到,获得积分10
9秒前
qianer完成签到 ,获得积分20
9秒前
伯赏汝燕发布了新的文献求助10
9秒前
漂亮豆芽发布了新的文献求助10
10秒前
janarbek完成签到,获得积分10
10秒前
害怕的冬云完成签到,获得积分10
11秒前
FashionBoy应助zzulyy采纳,获得10
11秒前
赵小超发布了新的文献求助30
11秒前
正能量完成签到,获得积分20
11秒前
13秒前
婷安wst完成签到,获得积分10
13秒前
风趣遥完成签到,获得积分10
13秒前
爱看文献的小羽毛完成签到,获得积分10
14秒前
元访琴完成签到,获得积分10
14秒前
loen完成签到,获得积分10
14秒前
15秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Technical Brochure TB 814: LPIT applications in HV gas insulated switchgear 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Picture Books with Same-sex Parented Families: Unintentional Censorship 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
A Preliminary Study on Correlation Between Independent Components of Facial Thermal Images and Subjective Assessment of Chronic Stress 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3970287
求助须知:如何正确求助?哪些是违规求助? 3515034
关于积分的说明 11176923
捐赠科研通 3250301
什么是DOI,文献DOI怎么找? 1795244
邀请新用户注册赠送积分活动 875732
科研通“疑难数据库(出版商)”最低求助积分说明 805039